ethyl 9-oxo-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-7-carboxylate | 864499-23-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 9-oxo-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-7-carboxylate
• 英文别名: Ethyl 9-oxo-5,6,7,8-tetrahydrocyclohepta[b]pyridine-7-carboxylate
• CAS: 864499-23-0
• 化学式: C₁₃H₁₅NO₃
• 分子量: 233.267
• InChiKey: OUYKPNZFTBXINJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  56.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 9-oxo-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-7-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 生成 9-Oxo-5,6,7,8-tetrahydrocyclohepta[b]pyridine-7-carboxylic acid
  参考文献：
  名称：

  A Novel Class of Cycloalkano[b]pyridines as Potent and Orally Active Opioid Receptor-like 1 Antagonists with Minimal Binding Affinity to the hERG K⁺Channel

  摘要：

  A series of compounds based on 7-{[4-(2-methylphenyl)piperidin-1-yl]methyl}-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-9-ol ((-)-8b), a potent and selective opioid receptor-like 1 (ORL1) antagonist, was prepared and evaluated using structure-activity relationship studies with the aim of removing its affinity to human ether-a-go-go related gene (hERG) K+ channel. From these studies, 10l was identified as an optimized structure with respect to ORL1 antagonist activity, and affinity to the hERG K+ channel. Furthermore, 10l showed good in vivo antagonism with a wide therapeutic index in regards to adverse cardiovascular effects.

  DOI：

  10.1021/jm701590h
• 作为产物：
  描述：

  5,6,7,8-四氢喹啉 在 吡啶 、 1,1'-azobis(cyclohexane)-1-carbonitrile 、 碘 、 三正丁基氢锡 、 sodium hydride 、 potassium hydrogencarbonate 、 臭氧 、 三苯基膦 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 、 乙酸酐 、 甲苯 为溶剂， 反应 93.5h， 生成 ethyl 9-oxo-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-7-carboxylate
  参考文献：
  名称：

  EP1726590

  摘要：

  公开号：

文献信息

• Tris(trimethylsilyl)silane promoted radical reaction and electron-transfer reaction in benzotrifluoride
  作者：Eietsu Hasegawa、Yuki Ogawa、Koji Kakinuma、Hiroyuki Tsuchida、Emi Tosaka、Shinya Takizawa、Hiroyasu Muraoka、Tomoko Saikawa

  DOI：10.1016/j.tet.2008.06.012

  日期：2008.8

  Tris(trimethylsilyl)silane (TTMSS) promoted free radical reaction in benzotrifluoride (BTF) was investigated. Compared to same reaction using environmentally less desirable tri-n-butyltin hydride (TBTH) in benzene, less quantity of BTF than that of benzene can be used because of slower hydrogen atom transfer from TTMSS than that from TBTH toward primary alkyl radicals. Also, electron-transfer reactions

  研究了三（三甲基甲硅烷基）硅烷（TTMSS）在苯并三氟化物（BTF）中促进的自由基反应。使用环境不太理想的三-相对于相同的反应Ñ苯-butyltin氢化物（TBTH），BTF的比苯的可以因为来自TTMSS较慢氢原子转移比从TBTH朝向初级烷基的使用量较少。另外，在BTF中进行了由三（对-溴苯基）六氯锑酸铵（TBPA）和FeCl 3促进的电子转移反应。然后，发现TBPA在BTF中的效果与在二氯甲烷中的效果相当。另外，有趣的观察表明FeCl 3加入咪唑鎓盐可促进反应的进行。所有结果表明，BTF是与TTMSS进行自由基反应和使用TBPA以及FeCl 3进行电子转移反应的可耐受溶剂。
• An Efficient and Convenient Synthesis of Tetrahydrocycloheptapyridines: New Precursors for CNS Agents
  作者：Takashi Yoshizumi、Hiroshi Miyazoe、Yuichi Sugimoto、Hirobumi Takahashi、Osamu Okamoto

  DOI：10.1055/s-2005-865306

  日期：——

  Development of a convenient and efficient synthetic route for functionalized tetrahydrocycloheptapyridines was accomplished by stepwise iodomethylation and subsequent radical ring expansion using a Bu 3 SnH/AIBN reaction system. Thus, 8- or 5-oxotetrahydroquinolines 4a and 4d and 8- or 5-oxotetrahydroiso-quinolines 4b and 4c afforded the 5,6,7,8-tetrahydrocycloheptapyridine-9-ones 3a and 3d and 6,7

  通过逐步碘甲基化和随后使用 Bu 3 SnH/AIBN 反应体系进行自由基扩环，开发了一种方便有效的官能化四氢环庚吡啶合成路线。因此，8-或 5-氧代四氢喹啉 4a 和 4d 以及 8-或 5-氧代四氢异喹啉 4b 和 4c 得到 5,6,7,8-四氢环庚吡啶-9-酮 3a 和 3d 以及 6,7,8,9-四氢环庚吡啶-5-酮 3b 和 3c，分别以中等总产率 (37-61%)。还发现该反应序列适用于其他杂环稠环庚酮的制备。
• Cycloalkanopyridine derivative
  申请人：Takahashi Hirobumi

  公开号：US20070191419A1

  公开（公告）日：2007-08-16

  Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.

  提供的是式[I]的环烷基吡啶衍生物：[其中符号与说明中所述相同]。这些化合物作为一种nociceptin受体拮抗剂，可用作与nociceptin受体相关的疾病的药物，例如作为缓解对麻醉镇痛剂的耐受性的药物；对麻醉镇痛剂的依赖或成瘾的缓解剂；镇痛增强剂；抗肥胖或食欲抑制剂；治疗或预防认知障碍和失忆症的药物；治疗发育性认知异常的药物；治疗精神分裂症的药物；治疗神经退行性疾病的药物；抗抑郁或治疗情感障碍的药物；治疗或预防尿崩症的药物；治疗或预防多尿症的药物；或治疗低血压的药物。
• CYCLOALKANOPYRIDINE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1726590A1

  公开（公告）日：2006-11-29

  Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.

  所提供的是式[I]的环烷吡啶衍生物： [其中符号与描述中的符号相同]。这些化合物具有痛觉素受体拮抗剂的作用，可作为治疗与痛觉素受体相关疾病的药物，例如，可作为麻醉镇痛剂耐受性的缓解剂；麻醉镇痛剂依赖或成瘾的缓解剂；镇痛增强剂；抗厌食或食欲抑制剂；治疗或预防认知障碍和痴呆/失忆症的药物；治疗发育性认知异常的药物；治疗精神分裂症的药物；治疗神经退行性疾病的药物；抗抑郁剂或治疗情感障碍的药物；治疗或预防糖尿病性尿崩症的药物；治疗或预防多尿症的药物；或治疗低血压的药物。
• US7855294B2
  申请人：——

  公开号：US7855294B2

  公开（公告）日：2010-12-21